HOME >> MEDICINE >> NEWS
Post-stent maintenance therapies questioned

e randomized, multi-center, double-blind, placebo controlled study of 2,022 patients undergoing PCI after pretreatment with clopidogrel were randomized to receive abciximab or placebo. The researchers measured for 30-day combined incidence of death, heart attack or urgent revascularization, as well as bleeding complications. The trial results show the role of the combination - intensive clopidogrel pretreatment plus abciximab - during PCI for ACS. They will enable us to know whether patients with ACS or any subset of them can benefit from this combination.

Dr. Kastrati will present the results of the "Prospective, Double Blind, Placebo-Controlled Trial of Glycoprotein IIb/IIIa Inhibition with Abciximab in Patients with Acute Coronary Syndromes Undergoing Stenting After Pretreatment with a High Loading Dose of Clopidogrel" (ISAR-REACT 2) study on Monday, March 13, at 2:40 p.m.


'"/>


14-Mar-2006


Page: 1 2

Related medicine news :

1. FDA approves Dey, L.P.s Perforomist inhalation solution for maintenance treatment of COPD
2. Internal medicine organizations survey internists on maintenance of certification
3. ASH Self-Assessment Program receives approval for maintenance of certification credit
4. Future therapies for stroke may block cell death
5. Antifolate therapies found effective against certain type of malaria
6. Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer
7. A sweet step toward new cancer therapies
8. Psychological therapies for common anxiety disorder not readily available in primary care settings
9. About 5 percent of adults with insomnia use alternative therapies
10. Combined therapies may boost immune response and long-term protection against brain tumors
11. New hope in cancer vaccines emerges as novel therapies are developed and tested

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Post stent maintenance therapies questioned

(Date:3/29/2015)... The Claudia Cohen Research Foundation and ... that Dr. Beth Y. Karlan has been selected as ... Prize for Outstanding Gynecologic Researcher. The $50,000 prize is ... Annual Meeting on Women's Cancer in Chicago. , Dr. ... at the Samuel Oschin Comprehensive Cancer Institute and Director ...
(Date:3/29/2015)... 2015 Final Cut Pro X ... Pixel Film Studios, entitled TranSports. , “TranSports is ... Final Cut Pro X,” said Christiana Austin, CEO of ... needed to effortlessly transition using this cool sports transition ... and uniquely styled transition pack for Final Cut Pro ...
(Date:3/28/2015)... 2015 Could genetic code determine someone’s ... study by researchers at the Harvard T.H. Chan ... support of the Coffee and Caffeine Genetics Consortium and ... past fall, the study—one of several recent HSPH investigations ... from more than 120,000 regular coffee drinkers of European ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs has prepared a ... during the Easter Holidays from today until April 6th. ... Fools’ Day. , As the winter fades and spring ... Festival, with religious origins to countries in Europe and ... The best wig provider, UniWigs, would like to offer ...
(Date:3/28/2015)... Pitching speed, player’s height, and pitching for multiple ... injuries, according to new research released today at the American ... , “Our findings indicate that a 10 inch increase in ... a history of injury, a 10 mile per hour increase ... a history of injury, and playing for more than one ...
Breaking Medicine News(10 mins):Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2
(Date:3/27/2015)... 27, 2015 As of February, InControl ... devices for women. "Shipping thousands of ... part is the hundreds of letters, emails and ... have been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution ...
(Date:3/27/2015)... , March 27, 2015  RXi Pharmaceuticals ... MirImmune LLC, today announced that they have ... RXi,s novel and proprietary sd-rxRNA® technology for ... The collaboration has the potential to result ... cancer treatments that could be a significant ...
(Date:3/27/2015)... YORK , March 27, 2015  Delcath ... pharmaceutical and medical device company focused on oncology ... and metastatic liver cancers, announces the reporting of ... Company,s Melphalan Hydrochloride for Injection with the Delcath ... a poster presentation at the Society of Surgical ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5
Cached News: